Senti Biosciences (SNTI) Other Non-Current Liabilities (2022 - 2025)

Senti Biosciences has reported Other Non-Current Liabilities for 4 years, with the latest figure at $8.1 million in Q4 2025.

• For the quarter ending Q4 2025, Other Non-Current Liabilities rose 60.41% year-over-year to $8.1 million; the trailing twelve-month figure through Dec 2025 stood at $8.1 million (up 60.41% YoY), and the FY2025 full-year result was $8.1 million, up 60.41% from the prior year.
• Other Non-Current Liabilities for Q4 2025 stood at $8.1 million, up from $7.6 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $8.1 million in Q4 2025, with the low at $20000.0 in Q2 2023.
• Average Other Non-Current Liabilities over 4 years is $3.1 million, with a median of $1.6 million recorded in 2022.
• Year-over-year, Other Non-Current Liabilities tumbled 97.53% in 2023 and surged 32695.0% in 2025.
• Tracing SNTI's Other Non-Current Liabilities over 4 years: stood at $227000.0 in 2022, then soared by 1670.93% to $4.0 million in 2023, then grew by 25.6% to $5.0 million in 2024, then surged by 60.41% to $8.1 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $8.1 million (Q4 2025), $7.6 million (Q3 2025), and $7.6 million (Q2 2025), per Business Quant data.

Peer Comparison